Kanurra Raises $6.5M to Make PBM Pricing Auditable

A benefits team can approve a pharmacy invoice without seeing the price paid to the pharmacy, the rebate collected from the manufacturer, or the margin retained between them. Kanurra is building a pharmacy benefit manager around exposing that chain, and the New York company has announced $6.5M in financing to take the model beyond a clean spreadsheet and into live employer health plans.

Founder and CEO Semih Gultekin is targeting self-funded and level-funded employers, particularly small and midsize groups that often receive pharmacy benefits inside a larger insurance or administration package. Kanurra says it charges one fixed per-employee-per-month fee, passes drug costs through without spread pricing, and credits 100% of rebates it receives back to the plan. The wager behind the financing is that auditability can become operating infrastructure rather than an annual argument over guarantees.

What Kanurra announced

Kanurra's September 29 company release names Necessary Ventures, Asylum Ventures, Daybreak Ventures, Virtue VC, Ford Street Ventures, and Browder Capital as investors. The company says the capital will help expand the number of covered lives and build infrastructure for partners and enrollees. Founder materials also point to hiring across clinical pharmacy, implementation and operations, broker and TPA-focused sales, and engineering.

The amount deserves precise accounting. The September release says $6.5M, while an earlier founder disclosure and several deal databases reported $6.35M from the same core investor group. Public evidence does not establish whether the difference is rounding or an incremental close, so the later company-issued figure supports the headline while the earlier number remains part of the record. Secondary deal sources classify the financing as Seed, although the company release does not state a formal round stage and does not identify a lead investor or valuation.

The business model hiding inside a prescription claim

A PBM sits between an employer health plan, a pharmacy, a drug manufacturer, and the member filling a prescription. The economics can include spread between what the plan is billed and what the pharmacy receives, retained manufacturer rebates, administrative charges, formulary economics, and affiliated-pharmacy revenue. A buyer may receive a performance summary without receiving enough claim-level detail to reconstruct who earned what.

This is not a theoretical complaint. A January 2025 Federal Trade Commission staff report found that the Big 3 PBMs' affiliated pharmacies marked up many analyzed specialty generic drugs by hundreds or thousands of percent. The report estimated more than $7.3B in dispensing revenue above estimated acquisition cost for those drugs from 2017 through 2022, plus an estimated $1.4B in spread-pricing income on the analyzed specialty generics.

Kanurra is positioning its economics against that structure. The company says the plan pays the pharmacy cost, sees rebates credited to the claim as they arrive, and pays Kanurra a separate fixed administrative fee that does not rise with drug spend. Its website presents claim-level ledgers that break out acquisition cost, dispensing fee, rebate, Kanurra markup, and final plan cost.

What the product must make visible

The product promise is larger than a lower invoice. Kanurra says employers can inspect claims, rebates, formulary decisions, and the criteria behind prior authorization. The company also says its AI can approve clean prior-authorization cases while routing anything outside the pathway to a licensed clinician, with AI barred from issuing denials. Those are company-reported operating claims, not independently audited performance results.

The same boundary applies to the savings examples on Kanurra's site. Its semaglutide illustration compares a $969 benchmark with a modeled $485 net plan cost after a $460 rebate and no markup, but the company labels the example as representative and notes that actual claims will differ. The useful claim is therefore auditability: a buyer should be able to test the math against its own utilization, contracts, and drug mix rather than accept a universal savings percentage.

Why this financing matters now

Gultekin's earlier announcement framed the problem through both personal medication affordability and employer drug costs he encountered in healthcare. Kanurra's official About page describes him as an AI engineer who built clinical and agentic healthcare systems and served as CTO of a healthcare-AI company through an acquisition. That background fits the product thesis, but the financing now has to turn technical fluency into a regulated service that works when a member needs a prescription.

The investor group is funding more than software development. A PBM must manage data exchange, network and adjudication relationships, clinical governance, employer implementation, member support, and distribution through brokers, consultants, and third-party administrators. Kanurra has also disclosed that its wholly owned Idaho pharmacy entity was formed on September 17, 2026 but had not yet received its pharmacy license, NPI, or NCPDP Provider ID and was not operating when the corporate-structure page was published.

The market test ahead

Kanurra says it had its first customers ready to go when Gultekin disclosed the financing, but public sources do not name those customers or report revenue, covered lives, audited savings, or renewal data. That keeps the important questions in view: whether employer groups can switch without material disruption, whether brokers can defend the economics to clients, and whether claim-level transparency survives the complexity of real formularies, specialty drugs, rebates, and prior authorization.

The financing gives Kanurra room to build the infrastructure and operating team required to answer those questions. Its sharper idea is that a benefits buyer should not need to trust the pharmacy invoice simply because the system is complicated. If Kanurra can make every dollar inspectable while carrying the clinical and administrative responsibility behind it, the company will have turned transparency from a promise into a working part of the benefit.